Lv41
600 积分 2021-05-07 加入
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
1年前
已完结
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
1年前
已完结
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
1年前
已完结
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
2年前
已完结
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
2年前
已完结
皖公网安备34019202002308
